3-n-Butylphthalide is a phthalide most strongly associated with celery seed chemistry, where it serves as one of the signature odor and composition markers of celery-type oils. Public evidence supports its identity, repeated occurrence in celery seed materials, and a larger pharmacology literature around dl- or l-3-n-butylphthalide as a neuroprotective drug context in China. That clinical and preclinical literature is relevant background, but it should be framed separately from aroma use because it largely concerns formulated drug use rather than consumer fragrance exposure.
Aroma and practical use
- Use the recorded celery-like, green, herbaceous, warm-spicy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The archive celery seed record places 3-n-butylphthalide at 2.1-3.0% with a typical value of 3.02%, confirming it as a meaningful but secondary celery-seed constituent rather than a trace impurity.
The archive celery seed record places 3-n-butylphthalide at 2.1-3.0% with a typical value of 3.02%, confirming it as a meaningful but secondary celery-seed constituent rather than a trace impurity.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A distillation optimization study on celery seed oil reported 3-n-butylphthalide at 13.1% in one recovered oil fraction, showing that phthalide abundance can rise substantially with process conditions.
A distillation optimization study on celery seed oil reported 3-n-butylphthalide at 13.1% in one recovered oil fraction, showing that phthalide abundance can rise substantially with process conditions.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2022 meta-analysis on acute ischemic stroke concluded that dl-3-n-butylphthalide reduced short-term death and neurological deficit while showing a good safety profile in the included trials.
A 2022 meta-analysis on acute ischemic stroke concluded that dl-3-n-butylphthalide reduced short-term death and neurological deficit while showing a good safety profile in the included trials.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2022 meta-analysis on post-stroke cognitive impairment found better cognitive and daily-living outcomes with NBP-containing interventions and reported no serious adverse reactions in the included studies, but also noted the need for higher-quality trials.
A 2022 meta-analysis on post-stroke cognitive impairment found better cognitive and daily-living outcomes with NBP-containing interventions and reported no serious adverse reactions in the included studies, but also noted the need for higher-quality trials.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The strongest public safety evidence located for 3-n-butylphthalide comes from oral clinical drug literature rather than topical fragrance exposure.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No constituent-specific public dermal maximum, IFRA restriction, or dedicated sensitization dossier for isolated 3-n-butylphthalide was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Clinical safety language for dl-3-n-butylphthalide should not be overextended to consumer essential-oil use because dose, route, and formulation differ substantially.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
Multi-pathway neuroprotection has been proposed in the drug literature, including oxidative-stress modulation, apoptosis/autophagy effects, cholinergic regulation, and neuroplasticity support.
These mechanisms come from the therapeutic NBP literature and should be treated as drug-context pharmacology rather than established aromatherapy mechanism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Most constituent-specific activity evidence is in therapeutic drug literature for dl- or l-3-n-butylphthalide rather than aroma-use exposure.
- No public constituent-specific dermal restriction or inhalation safety monograph was verified.
- Occurrence in celery materials is well supported, but standalone fragrance toxicology remains sparse.
- A dermal-limit safety pass (2026-07-13) searched IFRA/RIFM/ECHA/Tisserand sources for a 3-n-butylphthalide dermal limit and a topical sensitization dossier and found neither; the prior placeholder dermal_limit_pct of 0.8 and the unsupported sensitizing:true flag had no citation backing and were cleared to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.